Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06480605 in Moderate to Severe Ulcerative Colitis
NCT04090411Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 2 trial of afimkibart in ulcerative colitis (UC), sponsored by Roche. Started Dec 2019; status: completed.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04090411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090411.